BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31819089)

  • 1. New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma.
    Wan S; Kim TH; Smith KJ; Delaney R; Park GS; Guo H; Lin E; Plegue T; Kuo N; Steffes J; Leu C; Simeone DM; Razimulava N; Parikh ND; Nagrath S; Welling TH
    Sci Rep; 2019 Dec; 9(1):18575. PubMed ID: 31819089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
    Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
    Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay.
    Zhang Y; Zhang X; Zhang J; Sun B; Zheng L; Li J; Liu S; Sui G; Yin Z
    Cancer Biol Ther; 2016 Nov; 17(11):1177-1187. PubMed ID: 27662377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.
    Kalinich M; Bhan I; Kwan TT; Miyamoto DT; Javaid S; LiCausi JA; Milner JD; Hong X; Goyal L; Sil S; Choz M; Ho U; Kapur R; Muzikansky A; Zhang H; Weitz DA; Sequist LV; Ryan DP; Chung RT; Zhu AX; Isselbacher KJ; Ting DT; Toner M; Maheswaran S; Haber DA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1123-1128. PubMed ID: 28096363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.
    Qi LN; Xiang BD; Wu FX; Ye JZ; Zhong JH; Wang YY; Chen YY; Chen ZS; Ma L; Chen J; Gong WF; Han ZG; Lu Y; Shang JJ; Li LQ
    Cancer Res; 2018 Aug; 78(16):4731-4744. PubMed ID: 29915159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
    Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
    Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.
    Chu HY; Yang CY; Yeh PH; Hsu CJ; Chang LW; Chan WJ; Lin CP; Lyu YY; Wu WC; Lee CW; Wu JK; Jiang JK; Tseng FG
    Cells; 2021 May; 10(5):. PubMed ID: 34068719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1.
    Tang Y; Lu Y; Chen Y; Luo L; Cai L; Peng B; Huang W; Liao H; Zhao L; Pan M
    J Exp Clin Cancer Res; 2019 Nov; 38(1):473. PubMed ID: 31752959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.
    Ahn JC; Teng PC; Chen PJ; Posadas E; Tseng HR; Lu SC; Yang JD
    Hepatology; 2021 Jan; 73(1):422-436. PubMed ID: 32017145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved method increases sensitivity for circulating hepatocellular carcinoma cells.
    Liu HY; Qian HH; Zhang XF; Li J; Yang X; Sun B; Ma JY; Chen L; Yin ZF
    World J Gastroenterol; 2015 Mar; 21(10):2918-25. PubMed ID: 25780289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma.
    Cheng SW; Tsai HW; Lin YJ; Cheng PN; Chang YC; Yen CJ; Huang HP; Chuang YP; Chang TT; Lee CT; Chao A; Chou CY; Chan SH; Chow NH; Ho CL
    PLoS One; 2013; 8(11):e80053. PubMed ID: 24244607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
    Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
    Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
    Chen J; Cao SW; Cai Z; Zheng L; Wang Q
    Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantified postsurgical small cell size CTCs and EpCAM
    Wang L; Li Y; Xu J; Zhang A; Wang X; Tang R; Zhang X; Yin H; Liu M; Wang DD; Lin PP; Shen L; Dong J
    Cancer Lett; 2018 Jan; 412():99-107. PubMed ID: 29031565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.
    Cheng Y; Luo L; Zhang J; Zhou M; Tang Y; He G; Lu Y; Wang Z; Pan M
    J Gastrointest Surg; 2019 Dec; 23(12):2354-2361. PubMed ID: 30805878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study.
    Hamaoka M; Kobayashi T; Tanaka Y; Mashima H; Ohdan H
    PLoS One; 2019; 14(5):e0217586. PubMed ID: 31141571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.
    Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P
    Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis.
    Jin J; Niu X; Zou L; Li L; Li S; Han J; Zhang P; Song J; Xiao F
    Cancer Lett; 2016 Aug; 378(1):33-7. PubMed ID: 27160647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis.
    Cui K; Ou Y; Shen Y; Li S; Sun Z
    Medicine (Baltimore); 2020 Oct; 99(40):e22242. PubMed ID: 33019399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis.
    Zhang Y; Shi ZL; Yang X; Yin ZF
    World J Gastroenterol; 2014 Jan; 20(1):142-7. PubMed ID: 24415867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.